Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, midostaurin (Rydapt®) cannot be endorsed for use within NHS Wales for use as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia. |
||
|
||
Medicine details |
||
| Medicine name | midostaurin (Rydapt®) | |
| Formulation | 25 mg capsule | |
| Reference number | 3584 | |
| Indication | For use as monotherapy for the treatment of adult patients with aggressive systemic mastocytosis, systemic mastocytosis with associated haematological neoplasm, or mast cell leukaemia. |
|
| Company | Novartis Pharmaceuticals UK Ltd | |
| BNF chapter | Malignant disease & immunosuppression | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Ratification by Welsh Government | 08/12/2017 | |
| Date of issue | 12/12/2017 | |